We are thrilled to announce that Dia Beta Labs Ltd has successfully raised an impressive $1,200,000 in funding, marking a significant milestone in our mission to transform the management of diabetes and obesity-related health issues. With over 537 million adults currently affected by diabetes worldwide, and Type 2 Diabetes—predominantly driven by obesity—accounting for over 90% of these cases, the urgency for effective solutions has never been more pressing. Building upon more than 30 years of pioneering research from our esteemed founding group at Ulster University, Dia Beta Labs aims to harness the potential of next-generation therapeutics specifically designed for metabolic diseases. The funding will play a crucial role in accelerating our groundbreaking projects and studies, allowing us to develop innovative treatment options that not only address the symptoms of diabetes but also tackle the root causes of this global epidemic. Our commitment to impart significant and meaningful change in the management of the diabetes and obesity crisis is unwavering. This infusion of capital will enable us to advance our research initiatives, expand our team of experts, and expedite the road to bringing our transformative therapeutics to market. We extend our gratitude to our investors who share our vision for a healthier future and are joining us on this vital journey to combat one of the most pressing health challenges of our time. Together, we can create a world where metabolic diseases are effectively managed, offering hope and a better quality of life for millions facing these challenges.








